- Home
- Pelvic Health & Reconstruction
- Overactive Bladder
Overactive Bladder
Recent Abstracts
-
A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).Overactive BladderJune 18, 2017
-
Clinical utility of neurostimulation devices in the treatment of overactive bladder: current perspectives.Overactive BladderJune 18, 2017
-
Overactive Bladder Symptom Scores responsiveness before and after anticholinergic treatment in women with overactive bladder: The pilot study.Overactive BladderJune 18, 2017
-
Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies.Overactive BladderJune 10, 2017
-
[Food, diet and dietetic in treatment of urinary tract dysfunctions. A review].Overactive BladderJune 9, 2017
-
MicroRNAs as potential biomarkers to predict the risk of urinary retention following intradetrusor onabotulinumtoxin-A injection.Overactive BladderJune 9, 2017
-
Prevalence of overactive bladder and its impact on quality of life in 1025 patients with type 2 diabetes in mainland China.Overactive BladderMay 27, 2017
-
A case controlled study examining the bladder microbiome in women with Overactive Bladder (OAB) and healthy controls.Overactive BladderMay 27, 2017
-
Impact of 2015 Update to the Beers Criteria on Estimates of Prevalence and Costs Associated with Potentially Inappropriate Use of Antimuscarinics for Overactive Bladder.Overactive BladderMay 27, 2017
-
Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.Overactive BladderMay 22, 2017
Beyond the Abstracts
-
Impact of intravesical onabotulinumtoxinA on sexual function in women with OAB: Beyond the AbstractOveractive BladderJanuary 26, 2017
-
Readability Analysis of Online Health Information about Overactive Bladder: Beyond the AbstractOveractive BladderJanuary 18, 2017
-
Therapeutic potential of human chorionic gonadotropin against overactive bladder - Beyond the AbstractOveractive BladderJanuary 18, 2016
-
Real-World Patterns of Care for the Overactive Bladder (OAB) Syndrome in the United States - Beyond the AbstractOveractive BladderOctober 15, 2015
-
Overactive bladder syndrome, detrusor overactivity and the botulinum toxin - Beyond the AbstractOveractive BladderAugust 31, 2015
-
Refractory Overactive Bladder: A common problem? Beyond the AbstractOveractive BladderAugust 27, 2015
-
Neuromodulation for Overactive Bladder Symptoms in Women Utilizing Either Motor or Sensory/Motor Provocation With a Minimum Nine-Year Follow-Up - Beyond the AbstractOveractive BladderJuly 23, 2015
-
Solabegron: A potential future addition to the β-3 adrenoceptor agonist armamentarium for the management of overactive bladder, "Beyond the Abstract," by Pamela I. Ellsworth, MD, FACSOveractive BladderMay 14, 2015
-
Central inhibition of refractory overactive bladder complaints, results of an inpatient training program, "Beyond the Abstract," by Eelco F. J. Meijer, MD, MScOveractive BladderMarch 27, 2015
-
Intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment: Women's perspective, "Beyond the Abstract," by Pooja BalchandraOveractive BladderJuly 28, 2014
E-Newsletters
